Company pursuing a highly differentiated small molecule MOS-118 in Metabolic Obstructive Sleep Apnea. New investors, Supermoon Capital and HTGF, join founding investor Forty51 Ventures to complete the Seed syndicate. Company will use the funds to file an IND in preparation for a proof of mechanism and proof of concept in the clinic. Basel, Switzerland, April...Read More
BASEL, December 19, 2022 – Mosanna Therapeutics, a preclinical-stage Biotech company focused on developing MOS-118, a pharmacologic therapy to treat obstructive sleep apnea (OSA), today announced that the CEO will participate in the Partnering Forum at the Biotech Showcase 2023 taking place in San Francisco, January 9-11, and virtually between January 17-18. Meeting schedules will...Read More
BASEL, October 19, 2022 – Mosanna Therapeutics, a preclinical-stage Biotech company focused on developing MOS-118, a pharmacologic therapy to treat obstructive sleep apnea (OSA), today announced that the CEO will participate in the Partnering Forum at the BIO-EUROPE 2022 Conference taking place in Liepzig, Germany, October 24-26, and virtually between Nov 2-4, 2022. Meeting schedules...Read More
Company pursuing an advanced small molecule MOS-118 (formerly known as AVE0118) discovered by Sanofi. Experienced team with strong background in Metabolic Diseases and Obstructive Sleep Apnea. Seed financing led by Forty51 Ventures. Basel, Switzerland, July 13, 2022 /PRNewswire/ — Mosanna Therapeutics AG, a Swiss Biotech company today announced that it has secured seed financing led...Read More
